Multiple Myeloma is expected to hit 12,410 people this year, approximately 6840 men and 5570 women. The 5-year survival rate denotes the percentage of people who live for at least five years after being diagnosed with cancer. Percentage signifies how many out of a total of a hundred. People with multiple Myeloma have a 5-year survival rate of 54 percent.
The 5-year survival rate for the 5 percent of the people diagnosed at an early stage is 75 percent. If cancer has matured and spread to another part of the body, the 5-year survival rate is 53 percent. At this stage, around 95 percent of the cases get a diagnosis. Because survival rates have steadily increased over time, the 5-year survival rate may underestimate the impact of recent advances in treating multiple Myeloma. Furthermore, several factors influence an individual’s survival, such as age and overall health. For example, it is a fact that younger people have higher survival rates than older people.
It is critical to remember that statistics or the numbers on the survival rates of multiple Myeloma are only estimates. The estimate is based on the annual data on the number of people diagnosed with Multiple Myeloma in the USA. Medical experts also assess survival rates every half a decade. As a result, the estimate may not reflect on the results of the improved diagnosis or the treatment available in less than five years.
Myeloma or multiple Myeloma because most people (90% or more) have more than one bone lesion after diagnosis, or lesions develop throughout the illness.
Approximately 6000 new myeloma cases occur in the UK every year, with close to 16 people diagnosed with the disease every day. This is from the survey of 2016 – 2018. Myeloma is the 19th common cancer in the United Kingdom, accounting for 2 percent of new cancers.
Myeloma is the 18th most common cancer in females in the UK, with close to 2,500 new cases every year. It is the 16th most common cancer in males in the UK, with around 3400 new cases annually.
In the UK, incidence rates for Myeloma are the highest in people between 85 to 89. Every year, more than 4 out of 10, that is, around 40 percent of all new myeloma cases get a diagnosis in people of 75 and over.
The incidence rates have increased by 33 percent in the UK since the early ’90s, and the rates in males have increased by around 33 percent and in females around 21 percent.
In the last ten years, myeloma incidence rates have gone up to around 11% in the UK. 6% increase in females and about 13% in males.
The myeloma incidence rates are approximately estimated to rise by 11% in the UK from 2014 and 2035. This is projected to hit 12 cases for every 100,000 by the year 2035. The myeloma incidence rates in the UK in females are very similar in the most deprived decile compared with the least, and in males are similar in the most deprived quintile compared with the least (2013-2017). Myeloma is more common in black people than in white and also Asians. An estimation of 17,600 people who had previously been diagnosed with the disease survived in the UK at the end of 2010.
The mortality rate shows approximately 3100 deaths from this disease in the UK, more than 8 in 24 hours. Myeloma is the 17th most common cause of cancer death in the UK, accounting for 2% of cancer deaths. It is the 16th most common cause of death due to cancer in females, with around 1400 deaths in 2018.
Every year, around 61% of all myeloma deaths in the UK are in people aged 75 and above. It is the 16th most common cause of death in males, with approximately 1700 deaths in 2018. Mortality rates for the disease are the highest in people aged 85 to 89. Over the last ten years, myeloma mortality rates have hit a plateau state and have remained stable, and rates in males have remained stable. Mortality rates for Myeloma are projected to fall by 17% in the UK between 2014 and 2035, to 5 deaths per 100,000 people by the year 2035. For the last 50 years, myeloma mortality rates have increased by 60 % in the UK. Myeloma survival rates have improved and quadrupled over the UK’s previous four decades.